FWRD Leads EPS Revision Surge with 26.7% Gain; AEHR, RCEL Follow
Forward Air Corp (FWRD) surged 26.7% after its forward EPS growth estimate was raised from 69.4% to 78.0% on July 14. Aehr Test Systems (AEHR) gained 22.0% following a 20.0pp revision to 119.6%, backed by multiple analyst upgrades. AVITA Medical (RCEL) added 26.6% on a revised EPS estimate of 48.4%, while Airsculpt Technologies (AIRS) and Calumet (CLMT) posted double-digit gains on EPS upgrades.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| FWRD | Industrials | 2026-07-14 | +8.6pp | +26.7% |
| RCEL | Healthcare | 2026-07-14 | N/A | +26.6% |
| AEHR | Technology | 2026-07-17 | +20.0pp | +22.0% |
| AIRS | Healthcare | 2026-07-13 | N/A | +15.7% |
| CLMT | Basic Materials | 2026-07-13 | +8.1pp | +11.6% |
Why did FWRD stock jump in July 2026?
FWRD jumped 26.7% (from $12.79 to $16.21) after analysts raised its forward EPS growth estimate from 69.4% to 78.0% on July 14.
The revision was followed by the company announcing its Q2 2026 earnings release date on July 15, reinforcing optimism in Forward Air's expedited less-than-truckload and logistics business. The asset-light transportation provider's improved EPS outlook reflects expectations of stronger demand across its network.
FWRD EPS revision history → · Screener snapshot from 2026-07-14 →
FAQ: FWRD
Why did FWRD stock jump in July 2026?
FWRD surged 26.7% after analysts raised its forward EPS growth estimate from 69.4% to 78.0% on July 14, signaling improved profitability expectations.
Is FWRD a buy after the rally?
The 8.6 percentage-point EPS revision and positive earnings release announcement suggest continued analyst confidence, but investors should monitor Q2 results due August 5.
What is FWRD's EPS growth estimate?
Forward Air's forward EPS growth estimate was revised to 78.0% from 69.4%, a +8.6pp increase, as of July 14.
Why did RCEL stock jump in July 2026?
RCEL jumped 26.6% (from $4.02 to $5.09) after analysts raised its forward EPS growth estimate to 48.4% on July 14.
The revision came alongside AVITA Medical's announcement of its Q2 2026 earnings release date, reinforcing confidence in its wound care product pipeline. The healthcare company's improved earnings outlook suggests accelerating adoption of its regenerative therapies.
RCEL EPS revision history → · Screener snapshot from 2026-07-14 →
FAQ: RCEL
Why did RCEL stock jump in July 2026?
RCEL gained 26.6% after analysts revised its forward EPS growth estimate to 48.4% on July 14, with the catalyst of the Q2 earnings release announcement.
What caused RCEL's surge?
The surge was triggered by an upward EPS revision and the company's July 14 announcement of its Q2 2026 earnings conference call, boosting investor sentiment.
What is RCEL's EPS growth estimate?
AVITA Medical's forward EPS growth estimate stands at 48.4% following the revision detected on July 14.
Why did AEHR stock jump in July 2026?
AEHR jumped 22.0% (from $81.05 to $98.91) after analysts raised its forward EPS growth estimate from 99.6% to 119.6% on July 17.
The revision was reinforced by multiple analyst upgrades the same day, including Freedom Broker's upgrade to Buy with a $110 target, citing AI-driven semiconductor testing demand. Craig-Hallum and Lakestreet also raised price targets, projecting further upside from expanding data center growth.
AEHR EPS revision history → · Screener snapshot from 2026-07-17 →
FAQ: AEHR
Why did AEHR stock jump in July 2026?
AEHR jumped 22.0% after its forward EPS growth estimate was raised from 99.6% to 119.6% on July 17, supported by analyst upgrades citing AI demand.
Is AEHR a buy after the rally?
Multiple analysts raised price targets to $110-$130, implying further upside, but the stock has already surged 4X this year; valuation risk remains.
What is AEHR's EPS growth estimate?
Aehr Test Systems' forward EPS growth estimate was revised to 119.6% from 99.6%, a 20.0 percentage-point increase, as of July 17.
Why did AIRS stock jump in July 2026?
AIRS jumped 15.7% (from $4.20 to $4.86) after analysts raised its forward EPS growth estimate to 44.8% on July 13.
No earnings-related news accompanied the move, suggesting the revision alone drove the rally. The cosmetic procedure provider's improved profitability outlook likely reflects growing demand for its body sculpting services.
AIRS EPS revision history → · Screener snapshot from 2026-07-13 →
FAQ: AIRS
Why did AIRS stock jump in July 2026?
AIRS gained 15.7% after analysts revised its forward EPS growth estimate to 44.8% on July 13, with no other news catalysts.
What caused AIRS's surge?
The surge was solely driven by an upward EPS revision detected on July 13, indicating stronger earnings expectations for Airsculpt Technologies.
What is AIRS's EPS growth estimate?
Airsculpt Technologies' forward EPS growth estimate is 44.8% following the revision captured on July 13.
Why did CLMT stock jump in July 2026?
CLMT jumped 11.6% (from $39.58 to $44.17) after analysts raised its forward EPS growth estimate from 197.4% to 205.5% on July 13.
No earnings-related news emerged in the window, pointing to the revision as the primary catalyst. The specialty chemicals company's EPS upgrade signals optimism in its specialty products and renewable fuels segments.
CLMT EPS revision history → · Screener snapshot from 2026-07-13 →
FAQ: CLMT
Why did CLMT stock jump in July 2026?
CLMT rallied 11.6% after its forward EPS growth estimate was raised from 197.4% to 205.5% on July 13, with no additional news.
What is CLMT's EPS growth estimate?
Calumet's forward EPS growth estimate is 205.5%, up from 197.4% before the July 13 revision.
Is CLMT a buy after the rally?
The 8.1pp revision indicates strong earnings momentum, but lack of news warrants caution; monitor upcoming earnings for confirmation.
Today's top EPS revision plays—led by FWRD, RCEL, and AEHR—showcase the market's strong appetite for stocks with upward earnings estimate momentum, particularly in industrials, healthcare, and AI-driven technology. The absence of news for AIRS and CLMT highlights that pure revision signals can still trigger meaningful rallies.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →